Medical/Pharmaceuticals

Perennial Alzheimer's Care Village Xi'an Positioned as China's First and the World's Sixth Alzheimer's Care Village

Integrated Western and Eastern medicine, coupled with non-drug intervention therapies, sets international standards for Alzheimer's care inChina SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Perennial Holdings Private Limited (" Perennial Holdings") is pleased that Perennial Alzheimer's Care Village ("...

2024-11-18 18:31 3871

New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence

New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership withHealthcare Executi...

2024-11-18 16:00 1160

SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

TEL AVIV, Israel, Nov. 18, 2024 /PRNewswire/ -- SoniVie Ltd. , a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment ofRaymond W. Cohen to serve as its chairman of the board of directors. Mr. Coh...

2024-11-18 09:00 825

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

* Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering * Robust and sustainable treatment effects support at least bi-annual dosing regimen * Best-in-class potential of novel PC...

2024-11-18 09:00 1688

Boehringer Ingelheim Commits to Veeva Vault CRM

Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim is the latest global to...

2024-11-18 09:00 1119

Sky Labs' Wearable Device "Apollon" Recognized as an Honoree in CES 2025 Innovation Awards

SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- Sky Labs announced that its groundbreaking wearable device,Apollon, has been named an "Honoree" in the Artificial Intelligence category at the CES 2025 Innovation Awards. Hosted by the Consumer Technology Association (CTA)®, the CES Innovation Awa...

2024-11-18 08:00 1138

Getz Healthcare and IGEA Medical Announce Strategic Distribution Agreement to Introduce Adaptive Electroporation Technologies in Australia

This partnership aims to provide a new frontier in cancer care and vascular malformation treatment, offering clinicians cutting-edge technology to improve patient outcomes. SYDNEY, Nov. 18, 2024 /PRNewswire/ -- Getz Healthcare Australia is proud to announce a strategic distribution agreemen...

2024-11-18 07:30 944

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA

ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that a New Drug Applica...

2024-11-17 22:24 1450

International Cancer Organizations Present Collaborative Work During Oncology Event in China

The National Comprehensive Cancer Network (NCCN) is honored to participate in the 4th International Congress of the Asian Oncology Society and the Chinese Congress on Holistic Integrative Oncology (2024 CCHIO). XI'AN, China, Nov. 15, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network...

2024-11-15 09:04 1499

SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products BURLINGTON, Mass., Nov. 15, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGM...

2024-11-14 23:45 830

Lilly expands R&D footprint in Singapore with SGD$42 million investment in new Digital Health Innovation Hub

Lilly to drive next-generation AI-powered digital health technology research in Singapore SINGAPORE, Nov. 14, 2024 /PRNewswire/ -- Lilly Digital Health and Lilly Centre for Clinical Pharmacology (LCCP), a wholly owned subsidiary of U.S.-based Eli Lilly and Company (Lilly), today announced the e...

2024-11-14 15:10 1376

Sun Life Survey Reveals Hidden Financial and Mental Health Impacts of Type 2 Diabetes

* One third (33%) of those living with diabetes report a 'severe' or 'significant' financial impact on their lives, with 82% unable to consistently afford the right care.  * 67% of non-diabetics are either 'very concerned' or 'concerned' about the financial burden that would result from a typ...

2024-11-14 14:06 923

Suvoda Awarded US Patent for its eCOA Software Architecture

Low-code, no-code approach accelerates eCOA questionnaire design and deployment, taking questionnaire creation, licensing, and localization off the critical path  PHILADELPHIA, Nov. 14, 2024 /PRNewswire/ -- Suvoda, a global clinical trial technology company specializing in complex studies in the...

2024-11-14 09:00 1220

New Evidence-Based Information from NCCN Offers Tangible and Moral Support for People Trying to Quit Smoking

New NCCN Guidelines for Patients: Quitting Smoking showcases attainable and uplifting options that empower people with cancer to achieve better health outcomes. PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer ...

2024-11-13 21:06 1399

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug delivery, is excited to announce its official launch. The com...

2024-11-13 20:30 1180

NaoTrac Robot Pioneers Robotic Neurosurgery in Bolivia with Successful Brain Tumor Biopsies

HSINCHU, Nov. 13, 2024 /PRNewswire/ -- On November 5, 2024, Bolivia marked a historic moment in neurosurgery at Hospital Arcoiris, where two successful brain tumor biopsy surgeries were conducted using NaoTrac, the world's first autonomous surgical navigation robot. These groundbreaking surgeries...

2024-11-13 20:10 1609

Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

MELBOURNE, Australia and BERLIN, Germany, Nov. 13, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement withBerlin -based Eckert & Ziegler SE (EZAG) for the use of EZAG's cyclotro...

2024-11-13 16:18 1467

Clarivate Healthcare Business Insights Unveils 2023 Revenue Cycle Award Winners

Recognizing Roper St. Francis Healthcare, Bon Secours Mercy Health, and Bronson Methodist Hospital for excellence in Physician and Hospital Groups LONDON, Nov. 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the 2023 winners o...

2024-11-13 16:00 1090

Musim Mas Achieves a Top 5 Rank in the Global Child Forum Benchmark 2024

SINGAPORE, Nov. 13, 2024 /PRNewswire/ -- Musim Mas Group reached a significant milestone in the State of Children's Rights and Business 2024 Global Benchmark by Global Child Forum, achieving anoverall score of 9.3 out of 10, placing the Group in the top five of companies globally

2024-11-13 14:38 1342

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment

- CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment. - CBL-514 received both FDA Orphan Drug Designation and Fast Track designation for Dercum's disease treatment earlier this year. - CBL-514 Phase 2 study for Dercum's disease showed that it c...

2024-11-13 13:36 1116
12345 ... 396